Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE
- Development stage
- Unknown
- Lead developer
- Nerviano Medical Sciences
- Modality
- Small Molecules
01
Overview
This compound is a potent and selective inhibitor of cyclin-dependent kinase 2 (CDK2) with an IC50 of 20 nM. It belongs to the class of organic compounds known as benzenesulfonamides. The drug is used in research for its potential in cancer therapy due to its ability to inhibit cell cycle progression.
- Other names
- 4-{[5-(propan-2-yl)-1,3-thiazol-2-yl]amino}benzene-1-sulfonamide4-{[5-(1-methylethyl)-1,3-thiazol-2-yl]amino}benzenesulfonamide
02
Targets
CDK2 (Cyclin-dependent kinase 2)
Beyond the preview
Go deeper on 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE.